600416 Disclosed are 5-bicycloheteroarylalkyl-3-phenyl-124-triazole derivatives as represented by the general formula (I) wherein: HET-1 is a heteroaromatic group of formula II containing from 2 to 4 nitrogen atoms and which is preferably selected from [124]triazolo[15-a]pyridine [124]triazolo[15-a]pyrimidine or [124]triazolo[15-a]pyrazine and which may be optionally substituted; Q is phenyl optionally substituted with one to five substituents or a monocyclic 5-membered or 6-membered heteroaroma...

600416 Disclosed are 4-bicycloheteroarylalkyl-2-phenyl-imidazole derivatives as represented by the general formula (I) wherein: HET-1 is a heteroaromatic group of formula II containing from 2 to 4 nitrogen atoms and which is preferably selected from [124]triazolo[15-a]pyrazine or [124]triazolo[15-a]pyridine and which may be optionally substituted; Q is phenyl optionally substituted with one to five substituents or a monocyclic 5-membered or 6-membered heteroaromatic group containing 1 or 2 heter...

The present invention relates to a solid dosage form comprising an antipsychotic, particularly ziprasidone. The present invention also relates to a process for preparation of solid dosage form comprising ziprasidone.

The present invention relates to a process for preparing Ziprasidone of formula I or a pharmaceutically acceptable salt or a solvate or a hydrate thereof; comprising the steps of reacting 1-(12-benzisothiazol-3-yl) piperazine of formula II or its salt: with 5-(2-haloethyl)-6-chloro-oxindole of formula III: wherein X is leaving groups like fluoro chloro bromo iodo or sulphonyl; in the presence of a dispersing agent and a base in a solvent to form ziprasidone of formula I; and optionally convertin...

A process for the preparation of an acid addition salt of ziprasidone base and intermediates thereof comprising exposing the ziprasidone base in solid form to a gaseous acid in a substantially dry environment.